Education
About Us
Working with TipRanks
Follow Us
Artivion (AORT)
NYSE:AORT
AORT Stock Chart & Stats
$43.40
$0.30(1.03%)
At close: 4:00 PM EST
$43.40
$0.30(1.03%)
Day’s Range― - ―
52-Week Range$21.97 - $45.07
Previous CloseN/A
Volume97.41K
Average Volume (3M)365.73K
Market Cap
$2.05B
Enterprise Value$1.62B
Total Cash (Recent Filing)$53.48M
Total Debt (Recent Filing)$8.79M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 06, 2025EPS Estimate
0.02Last Dividend Ex-Date
Dec 09, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding47,183,660
10 Day Avg. Volume246,451
30 Day Avg. Volume365,734
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue4.00
Enterprise Value/Gross Profit6.26
Enterprise Value/Ebitda40.73
Forecast
1Y Price Target
$45.26Price Target Upside4.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceArtivion beat revenue and adjusted EBITDA estimates, leading to an increase in its fiscal year guidance.
Market ExpansionOngoing market share gains for On-X are driven by the lower patient warfarin requirement compared to competitors, making it a preferred choice among physicians.
Product GrowthThe On-X mechanical heart valve business showed a robust and unexpectedly positive growth performance, contributing significantly to Artivion's revenues.
Bears Say
Operational RecoveryArtivion is recovering well from the previous cyber-attack, with its tissue business sales ramping back up, positioning the company for acceleration and recovery.
Regulatory ChallengesEndospan expects to submit its PMA to the FDA after 12-month data from the trial is available, putting it on track for FDA approval in late 2026.
Stock DependencyThe company launched AMDS under HDE, which carries a strong initial stocking benefit, and most of the revenue thus far has been from stocking, according to the company.
Artivion News
AORT FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was $21.97 and its highest was $45.07 in the past 12 months.
What is Artivion’s market cap?
Artivion’s market cap is $2.05B.
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is Nov 06, 2025 which is in 11 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Aug 07, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.034.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is 0.02.
How many shares outstanding does Artivion have?
Artivion has 47,183,660 shares outstanding.
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went up 25.229%.
Which hedge fund is a major shareholder of Artivion?
Currently, no hedge funds are holding shares in AORT
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.26 (4.29% Upside)
$45.26 (4.29% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 67.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.57%
12-Months-Change
Fundamentals
Return on Equity
-5.01%
Trailing 12-Months
Asset Growth
6.19%
Trailing 12-Months
Company Description
Artivion
Artivion, Inc. (AORT) is a medical technology company specializing in the development and commercialization of innovative surgical solutions for the treatment of cardiovascular diseases. The company primarily focuses on advanced bioengineered heart valves and minimally invasive surgical technologies, aiming to improve patient outcomes and reduce healthcare costs. Artivion's core products include its AORTIC® and PERIMOUNT® heart valve offerings, as well as its innovative surgical devices that are designed to assist in various cardiovascular procedures.
AORT Company Deck
AORT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong revenue and EBITDA growth, particularly in the On-X and stent graft segments, alongside a significantly improved balance sheet. While there are some challenges from past cybersecurity incidents and slower growth in tissue processing and BioGlue, the overall performance and outlook are favorable.View all AORT earnings summariesAORT Stock 12 Month Forecast
Average Price Target
$45.26
▲(4.29% Upside)
Technical Analysis
Ownership Overview
4.87% Insiders
30.15% Mutual Funds
0.02% Other Institutional Investors
46.37% Public Companies and
Individual Investors